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Abstract 
Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous rash 
characterized by widespread sterile nonfollicular pustules. Cefepime is a fourth 
generation cephalosporin, used to treat severe infections. A 67-year-old man was 
admitted with acute gastroenterocolitis. On the seventh day, the patient developed a 
nosocomial pneumonia and cefepime was initiated. On the fourth day of cephalosporin 
treatment, he presented with a maculopapular, pruritic eruption affecting the face, neck, 
abdomen and limbs. One day later he developed disseminated pustular lesions and his 
temperature was 37°C. Laboratory analysis evidenced leukocytosis and skin biopsy 
showed subcorneal pustule, edema in the papillary dermis, perivascular inflammatory 
infiltrate consisting of neutrophils, leukocytoclasia and red cell extravasation in the 
epidermis. Cefepime was suspended and within 4 days the non-follicular pustules 
cleared following a desquamation. AGEP is a disease attributed to a variety of causes, but 
in 90% of the cases it is due to an adverse drug reaction. Antibiotics are implicated in 
80% of these cases, mostly penicillins and macrolides. There are few cases associated 
with cephalosporins. It is very important to consider AGEP in cases of acute pustular 
rashes and drugs should be investigated as causative agents. 
 
Introduction 
Acute generalized exanthematous pustulosis (AGEP) is a rare acute reaction that is 
drug-induced in 90% of the cases [1], characterized by a widespread, sterile pustular rash. 
Pustules resolve spontaneously within a few days.  
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Cefepime is a fourth generation cephalosporin antibiotic used to treat febrile 
neutropenia, severe infections related to the urinary tract, skin, nosocomial pneumonia, 
brain abscess, and intra-abdominal and septic lateral/cavernous sinus thrombosis [2]. 
Case Report 
A 67-year-old man with renal failure who had been on dialysis during the last 2 years and with an 
8-year history of cardiac insufficiency was admitted to the hospital complaining of 6 days of diarrhea. 
He was hypotensive and dehydrated at admission. The patient was taken to the semi-intensive care unit 
and treated with ciprofloxacin. As a consequence, his diarrhea resolved on the sixth day after admission. 
His long-term medications had not been changed and consisted of acetylsalicylic acid, furosemide, 
captopril, carvedilol and clonazepam. On the seventh day, the patient became dyspneic and his chest 
radiograph showed a left lower lobe opacity. Treatment for nosocomial pneumonia was promptly 
initiated with cefepime (1 g/day). Five days later, he presented with a pruritic, erythematous, 
maculopapular eruption affecting the abdomen, neck and skin folds. One day later, he developed 
disseminated pustular lesions (fig. 1) and his temperature was 37°C. Laboratory exams evidenced 
C-reactive protein 136 mg/l, white blood cells 14,700 cells/μl (normal 3,500–10,500 cells/μl) with 11,995 
cells/μl neutrophils (normal 1,700–8,000 cells/μl). Histology showed a toxic pustuloderma with 
spongiform subcorneal pustules, edema in the papillary dermis and perivascular inflammatory infiltrate 
consisting of neutrophils (fig. 2). Leukocytoclasis and red cell extravasation in the epidermis were 
present. After withdrawal of cefepime and introduction of imipenem, the disseminated skin 
nonfollicular pustules cleared within 4 days following a desquamation. The patient denied previous 
adverse reaction to other drugs and no personal or family history of psoriasis was evident. He was 
discharged from the hospital on day 19 after admission. 
Discussion 
AGEP is a disease characterized by the rapid onset of many sterile, nonfollicular 
pustules usually arising on an edematous erythema and frequently accompanied by 
leukocytosis and fever. Skin symptoms usually arise rapidly after an insult and resolve 
spontaneously (within a few days). AGEP often starts predominantly in intertriginous 
areas or on the face, spreading rapidly to the trunk and lower limbs. The mean duration 
of the pustules is 9.7 days, and an annular desquamation typically follows for a few days. 
Complications are rare [1, 3]. The AGEP validation score of the EuroSCAR study group 
has been used to establish the diagnosis [4]. A score between 8 and 12 for AGEP is a 
definitive diagnosis (table 1). The case score was 11, according to the validation score of 
the EuroSCAR study group (table 2). 
The main differential diagnosis of AGEP is pustular psoriasis. Because the pustules 
clinically and histologically resemble the lesions of pustular psoriasis and because in a 
number of reports patients had a history of plaque psoriasis, some authors assume that 
AGEP is nothing more than an acute exacerbation of psoriasis caused by a variety of 
exogenous triggers. However, many studies strongly suggest that AGEP is not associated 
with psoriasis [1, 5]. 
Up to now AGEP has been attributed to a variety of causes such as viral infections [6–
10], Chlamydia pneumoniae infection [11] or hypersensitivity to mercury [12], but the 
skin reaction is primarily an adverse response to drugs. Antibiotics, other than cefepime, 
have been implicated as the causative agents in 80% of individuals [13]. In this group, the 
disease is usually caused by penicillins or macrolides [14, 15]. The present case of AGEP 
has well defined criteria, and because correct diagnosis generally leads to spontaneous 
resolution once the causative drug is withdrawn, clinicians should keep the possibility of 
this cutaneous drug reaction in mind.  
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Table 1. AGEP validation score of EuroSCAR study group 
Variable Score  Variable  0Score
Morphology 
Pustules 
Typical*  
Compatible**  
Insufficient***  
Erythema 
Typical  
Compatible  
Insufficient 
Distribution/pattern 
Typical  
Compatible 
Insufficient  
Postpustular desquamation 
Yes 
No/insufficient  
 
 
+2 
+1 
+0 
 
+2 
+1 
+0 
 
+2 
+1 
+0 
 
+1 
+0 
Course 
Mucosal involvement 
Yes  
No  
Acute onset (<10 d) 
Yes  
No  
Resolution <15 days 
Yes  
No  
Fever >38.75°C 
Yes  
No 
Polymorphonuclear neutrophils >7,000/mm
3 
Yes  
No  
 
 
0–2 
+00 
 
+00 
0–2 
 
+00 
0–4 
 
0+1 
+00 
 
0+1 
+00 
   Histology 
Other disease  
Not representative/no histology 
Exocytosis of PMN  
Subcorneal and/or intraepidermal 
non-spongiform or NOS pustule(s)  
with papillary edema  
or 
subcorneal and/or intraepidermal spongiform 
or NOS pustule(s) without papillary edema 
Spongiform subcorneal and/or intraepidermal 
pustule(s) with papillary edema 
 
–10 
+00 
0+1 
 
 
 
 
 
0+2 
 
0+3 
NOS = not otherwise specified. 
Interpretation: ≤0: no AGEP; 1–4: possible; 5–7: probable; 8–12: definite. 
* Typical: typical morphology. 
** Compatible: not typical, but not strongly suggestive of other disease. 
*** Insufficient: lesions cannot be judged. 
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Table 2. Patient AGEP score, according to EuroSCAR study group 
Variable Score 
Morphology   
Pustules  
Typical +2 
Erythema  
Typical +2 
Distribution/pattern  
Typical +2 
Postpustular desquamation   
Yes   +1 
Course   
Mucosal involvement   
No   +0 
Acute onset (<10 days)   
Yes   +0 
Resolution <15 days   
Yes   +0 
Fever >38.75°C   
No  +0 
Polymorphonuclear neutrophils >7,000/mm
3  
Yes   +1 
Histology   
Spongiform subcorneal and/or intraepidermal 
pustule(s) with papillary edema 
 
+3 
 
 
 
 
Fig. 1. Pustular lesions affecting the neck. 
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Fig. 2. Histology showed a toxic pustuloderma with spongiform subcorneal pustule and perivascular 
inflammatory infiltrate consisting of neutrophils. 
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